Samjin Pharmaceuticals Co., Ltd. (005500.KS)
KRW 18280.0
(-0.33%)
KRW 18280.0
(-0.33%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 18.9 Billion KRW | -13.65% |
| 2022 | 21.89 Billion KRW | -22.92% |
| 2021 | 28.4 Billion KRW | 1.88% |
| 2020 | 27.87 Billion KRW | 134.66% |
| 2019 | 11.88 Billion KRW | -53.46% |
| 2018 | 25.52 Billion KRW | -28.69% |
| 2017 | 35.79 Billion KRW | 18.63% |
| 2016 | 30.17 Billion KRW | 11.58% |
| 2015 | 27.04 Billion KRW | 30.54% |
| 2014 | 20.71 Billion KRW | 162.96% |
| 2013 | 7.87 Billion KRW | -25.95% |
| 2012 | 10.63 Billion KRW | 50.63% |
| 2011 | 7.06 Billion KRW | -32.59% |
| 2010 | 10.47 Billion KRW | 48.72% |
| 2009 | 7.04 Billion KRW | 4.65% |
| 2008 | 6.73 Billion KRW | 4.62% |
| 2007 | 6.43 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 3.09 Billion KRW | -57.99% |
| 2024 Q2 | 24.79 Billion KRW | 700.02% |
| 2023 Q4 | 7.37 Billion KRW | 134.72% |
| 2023 FY | 18.9 Billion KRW | -13.65% |
| 2023 Q1 | 8.76 Billion KRW | -10.58% |
| 2023 Q2 | 812.53 Million KRW | -90.73% |
| 2023 Q3 | 3.14 Billion KRW | 286.75% |
| 2022 FY | 21.89 Billion KRW | -22.92% |
| 2022 Q3 | 4.28 Billion KRW | 2.23% |
| 2022 Q4 | 9.79 Billion KRW | 128.9% |
| 2022 Q1 | 3.62 Billion KRW | 249.93% |
| 2022 Q2 | 4.18 Billion KRW | 15.41% |
| 2021 Q2 | 8.21 Billion KRW | 20.83% |
| 2021 Q4 | -2.41 Billion KRW | -115.29% |
| 2021 Q3 | 15.82 Billion KRW | 92.55% |
| 2021 FY | 28.4 Billion KRW | 1.88% |
| 2021 Q1 | 6.79 Billion KRW | 15.15% |
| 2020 FY | 27.87 Billion KRW | 134.66% |
| 2020 Q1 | 8.48 Billion KRW | 258.74% |
| 2020 Q3 | 5.45 Billion KRW | -32.08% |
| 2020 Q4 | 5.9 Billion KRW | 8.25% |
| 2020 Q2 | 8.03 Billion KRW | -5.36% |
| 2019 Q1 | 11.46 Billion KRW | 235.04% |
| 2019 Q2 | -11.14 Billion KRW | -197.21% |
| 2019 Q4 | 2.36 Billion KRW | -74.27% |
| 2019 FY | 11.88 Billion KRW | -53.46% |
| 2019 Q3 | 9.19 Billion KRW | 182.5% |
| 2018 Q4 | -8.49 Billion KRW | -174.01% |
| 2018 FY | 25.52 Billion KRW | -28.69% |
| 2018 Q3 | 11.47 Billion KRW | -2.43% |
| 2018 Q2 | 11.75 Billion KRW | 9.02% |
| 2018 Q1 | 10.78 Billion KRW | 54.93% |
| 2017 Q1 | 8.59 Billion KRW | 83.68% |
| 2017 Q2 | 9.72 Billion KRW | 13.11% |
| 2017 Q3 | 10.51 Billion KRW | 8.22% |
| 2017 FY | 35.79 Billion KRW | 18.63% |
| 2017 Q4 | 6.96 Billion KRW | -33.82% |
| 2016 Q4 | 4.67 Billion KRW | -48.69% |
| 2016 Q1 | 8.05 Billion KRW | 34.37% |
| 2016 FY | 30.17 Billion KRW | 11.58% |
| 2016 Q2 | 8.32 Billion KRW | 3.35% |
| 2016 Q3 | 9.11 Billion KRW | 9.53% |
| 2015 Q4 | 5.99 Billion KRW | -17.8% |
| 2015 Q2 | 7.16 Billion KRW | 8.69% |
| 2015 FY | 27.04 Billion KRW | 30.54% |
| 2015 Q3 | 7.29 Billion KRW | 1.77% |
| 2015 Q1 | 6.59 Billion KRW | 160.85% |
| 2014 Q2 | 5.91 Billion KRW | -8.44% |
| 2014 Q1 | 6.46 Billion KRW | 27.7% |
| 2014 FY | 20.71 Billion KRW | 162.96% |
| 2014 Q4 | 2.52 Billion KRW | -56.5% |
| 2014 Q3 | 5.8 Billion KRW | -1.81% |
| 2013 Q3 | 5.54 Billion KRW | 162.97% |
| 2013 FY | 7.87 Billion KRW | -25.95% |
| 2013 Q2 | -8.8 Billion KRW | -244.88% |
| 2013 Q1 | 6.07 Billion KRW | 121.08% |
| 2013 Q4 | 5.06 Billion KRW | -8.75% |
| 2012 Q1 | 2.01 Billion KRW | 377.77% |
| 2012 Q2 | 2.38 Billion KRW | 17.94% |
| 2012 Q3 | 3.48 Billion KRW | 46.38% |
| 2012 Q4 | 2.74 Billion KRW | -21.14% |
| 2012 FY | 10.63 Billion KRW | 50.63% |
| 2011 Q4 | -727.1 Million KRW | -120.75% |
| 2011 Q1 | 4.13 Billion KRW | 158.46% |
| 2011 Q2 | 150.43 Million KRW | -96.36% |
| 2011 FY | 7.06 Billion KRW | -32.59% |
| 2011 Q3 | 3.5 Billion KRW | 2229.72% |
| 2010 FY | 10.47 Billion KRW | 48.72% |
| 2010 Q2 | 2.01 Billion KRW | -40.21% |
| 2010 Q3 | 3.48 Billion KRW | 72.49% |
| 2010 Q1 | 3.37 Billion KRW | 2183.57% |
| 2010 Q4 | 1.59 Billion KRW | -54.07% |
| 2009 Q3 | 1.69 Billion KRW | -16.15% |
| 2009 Q4 | 147.85 Million KRW | -91.3% |
| 2009 Q1 | 3.17 Billion KRW | 686.24% |
| 2009 FY | 7.04 Billion KRW | 4.65% |
| 2009 Q2 | 2.02 Billion KRW | -36.14% |
| 2008 Q3 | 1.18 Billion KRW | -41.33% |
| 2008 Q4 | 403.5 Million KRW | -65.87% |
| 2008 FY | 6.73 Billion KRW | 4.62% |
| 2008 Q1 | 3.13 Billion KRW | 1352.24% |
| 2008 Q2 | 2.01 Billion KRW | -35.66% |
| 2007 Q1 | 3.07 Billion KRW | 0.0% |
| 2007 Q3 | 1.13 Billion KRW | -43.7% |
| 2007 Q2 | 2.01 Billion KRW | -34.53% |
| 2007 FY | 6.43 Billion KRW | 0.0% |
| 2007 Q4 | 215.63 Million KRW | -80.97% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 363.279% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 67.398% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 131.728% |
| HANDOK Inc. | -28.79 Billion KRW | 165.651% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 324.663% |
| Yuhan Corporation | 93.5 Billion KRW | 79.782% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | -69.978% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 176.196% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 87.071% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -438.84% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 854.296% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 1011.601% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 517.822% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 15.345% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 363.279% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 190.282% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -427.597% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 115.985% |
| JW Holdings Corporation | 19.02 Billion KRW | 0.633% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 123.953% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 91.104% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 48.912% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 132.98% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | -208.829% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -1036.479% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -277.757% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 363.279% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 48.856% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 83.044% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 48.912% |
| Yuhan Corporation | 93.5 Billion KRW | 79.782% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 216.345% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 587.823% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -208.957% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 48.912% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 60.827% |
| CKD Bio Corp. | -24.19 Billion KRW | 178.147% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 20.952% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 31.097% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 36.503% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 132.98% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 59.781% |
| Boryung Corporation | 40.2 Billion KRW | 52.974% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 160.345% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 854.296% |
| JW Lifescience Corporation | 28.14 Billion KRW | 32.825% |